Clinical trial
Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer
NCT00130520 · University of Arizona, Other · Completed
Key facts
| NCT number | NCT00130520 |
|---|---|
| Title | Bevacizumab and Erlotinib Study in Advanced Ovarian Cancer |
| Official title | Phase II Open-Label Trial of Erlotinib (Tarceva) and Bevacizumab in Women With Advanced Ovarian Cancer |
| Lead sponsor | University of Arizona, Other |
| Collaborators | Genentech, Inc. Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ovarian Neoplasms |
| Intervention type | Drug |
| Interventions | bevacizumab, erlotinib |
| Enrollment | 40 |
| Start date | Jun 1, 2005 |
| Primary completion | Jan 1, 2010 |
| Completion | May 1, 2010 |
| First posted | Aug 15, 2005 |
| Last update posted | May 28, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: